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We read with great interest the paper by Petraco et al. (1) evalu-
ating the effects of fractional ﬂow reserve (FFR) measurement
variability on FFR-guided treatment strategy. It was suggested
that clinicians should make revascularization decisions based on
broadened clinical judgment when FFR values fall in the 0.75 to
0.85 biological variability zone, particularly between 0.77 and 0.83.
However, we have several concerns and suggestions with regard to
the design of the study.
First, the study analyzed the FFR reproducibility data from the
landmark DEFER (Deferral Versus Performance of PTCA in
Patients Without Documented Ischemia) study (2). The algorithm
was an ingenious design, but the data, which was established a
decade ago, inversely limited the management and ﬂexibility of the
design. As we notice, in the same lesion, the rigid time interval of
the repeated FFR measurements was 10 min apart, which was not
discussed in the study by Petraco et al. (1) or the DEFER study (2).
It might be explained as a habit and the experience of cardiologists,
but the attempt to design a series of time intervalsdsuch as 5 min,
10 min, and 15 mindis not achievable when exploring the time-
saving strategy and the necessity of repeating times. Furthermore,
incorporation of robust data from the FAME (Fractional Flow
Reserve Versus Angiography for Multivessel Evaluation) (3) and
FAME II (Fractional Flow Reserve [FFR] Guided Percutaneous
Coronary Intervention [PCI] Plus Optimal Medical Treatment
[OMT] Versus OMT) (4) studies might add to the scalability of
the analysis.
Second, only the cutoff of 0.80 was analyzed, and the further
away a single FFR value falls from the 0.80 cutoff, the greater the
certainty that the recommended treatment strategy will not be
reversed when the test is repeated. This could be interpreted as a
ﬂaw using the cutoff of 0.80, though it has a sensitivity of more
than 90% (5) and is recommended by the current guideline (6).
However, the guideline also noted that “FFR measurements <0.75
are associated with ischemia on exercise testing and adjunct im-
aging (echo or nuclear) with high sensitivity (88%), speciﬁcity
(100%), and overall accuracy (93%)” (6). Thus, it would be ad-
visable to incorporate the cutoff of 0.75 into the analysis in parallel,
which might turn out to be a narrower measurement gray zone
compared with the cutoff of 0.80.
Finally, the study suggested that clinicians should make
revascularization decisions based on broadened clinical judgment
when a single FFR result fell within 0.75 to 0.85, particularly
between 0.77 and 0.83. Nevertheless, in daily practice, few clini-
cians would make a revascularization decision merely based on the
value of FFR without the consideration of other available infor-
mation such as clinical symptoms, anatomic features, risk–beneﬁt
proﬁle, and even the ﬁnancial burden of the patients. A bettersuggestion might be repeating the FFR measurement more times
to make the revascularization decision when a single FFR result
falls within 0.75 to 0.85, particularly between 0.77 and 0.83.
Again, back to the inherent limitations of the reproducibility data,
the optimal number of times to repeat the measurement is worth
exploring.
In summary, we appreciate the ingenuity of the study, but
we believe that our suggestions may make a more compelling
argument.
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